Sarepta Therapeutics, Inc. (SRPT)
Automate Your Wheel Strategy on SRPT
With Tiblio's Option Bot, you can configure your own wheel strategy including SRPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
Published: March 20, 2026 by: Zacks Investment Research
Sentiment: Positive
SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.
Read More
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne. “Since this program began nine years ago, significant progress has b.
Read More
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Neutral
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
Read More
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
Published: February 24, 2026 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co., Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. Elevidys is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory indivi.
Read More
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
Read More
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Published: January 26, 2026 by: Seeking Alpha
Sentiment: Neutral
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Read More
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
Published: January 26, 2026 by: Proactive Investors
Sentiment: Positive
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3 EMBARK study evaluating its gene therapy ELEVIDYS in ambulatory patients with Duchenne muscular dystrophy. Sarepta said patients treated with ELEVIDYS demonstrated statistically significant and clinically meaningful slowing of disease progression across key functional measures compared with an untreated external control group.
Read More
Sarepta Therapeutics: Is Elevidys A Bust?
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Negative
Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management reiterates a $500M annual revenue floor and expects normalization in ambulatory demand to support growth. SRPT fundamentals are robust, with nearly $1B in cash, no near-term debt, and a stable PMO franchise generating almost $1B in 2025 revenue.
Read More
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Published: January 12, 2026 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Financial Update* (preliminary and unaudited) Total net product revenu.
Read More
Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty
Published: January 12, 2026 by: Newsfile Corp
Sentiment: Neutral
San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) concerning whether certain officers and directors breached their fiduciary duties to the Company and its shareholders. The investigation follows the filing of a securities class action involving purchases of Sarepta securities between June 22, 2023 and June 24, 2025 (the "Class Period").
Read More
Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Read More
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
Read More
Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information
Published: November 14, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy (DMD). As previously disclosed, the ELEVIDYS label now includes several key updates, including: A boxed warning for the risk of acute serious liver injury (ALI) and acute liver failure (ALF).
Read More
US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries
Published: November 14, 2025 by: Reuters
Sentiment: Negative
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys that includes its most serious safety warning and restricts use of the treatment to walking patients with Duchenne muscular dystrophy.
Read More
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
Read More
Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Negative
Sarepta Therapeutics, Inc. faces uncertainty after Elevidys' revenue decline and ESSENCE trial failure, leading to a 25% SRPT stock drop. SRPT's PMO franchise remains its cash engine, but regulatory reliance on real-world evidence and FDA unpredictability add risk to the investment thesis. Label contraction for Elevidys and margin pressures weigh on near-term outlook, with upside catalysts mostly expected in 2026 from RNA therapeutics data.
Read More
Sarepta Therapeutics Stock Tumbles After Trial Data
Published: November 04, 2025 by: Schaeffers Research
Sentiment: Negative
Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance.
Read More
Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline
Published: October 10, 2025 by: Seeking Alpha
Sentiment: Positive
Sarepta Therapeutics is showing signs of recovery, driven by its robust pipeline and recent revenue growth, despite past clinical setbacks. SRPT's near-term catalyst is SRP-9003, a gene therapy for Limb-Girdle Muscular Dystrophy, with pivotal Phase 3 data expected in late 2025 or early 2026. Valuation remains attractive, with SRPT trading at a discount to peers and holding a strong cash position, while upcoming data could drive significant upside.
Read More
What's Going On Sarepta Stock On Wednesday?
Published: October 08, 2025 by: Benzinga
Sentiment: Neutral
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.
Read More
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress, taking place Oct. 7-11, 2025, in Vienna, Austria. Sarepta presentations will include results from several studies in the delandistrogene moxeparvovec clinical development program, as well as a real-world evidence study of pulmonary function in advanced-stage patients with.
Read More
Kuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) breached their fiduciary duties to shareholders.
Read More
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
Published: September 05, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne. Now in its eighth year, the program was created to recognize individuals living with Duchenne muscular dystro.
Read More
SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action
Published: August 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies for the treatment of rare diseases.
Read More
About Sarepta Therapeutics, Inc. (SRPT)
- IPO Date 1997-06-04
- Website https://www.sarepta.com
- Industry Biotechnology
- CEO Douglas S. Ingram
- Employees 1372